Learn About Resistant Hypertension on CME Webcast

OSUWexnerbloglogo2014 Learn About Resistant Hypertension on CME Webcast. Most of the time, treatment works. But sometimes, treatment is not successful, resulting in resistant hypertension. On this CME webcast, we’re going to be discussing resistant hypertension. Joining our moderator in the studio are hypertension experts from the Ohio State University. Dr. Christopher Chiu is an Assistant Professor of Internal Medicine and Dr. Rima Kang is also an Assistant Professor of Internal Medicine, both from the Division of General Internal Medicine.

View a video introduction of this webcast

What you’ll learn in this webcast

As a result of this educational activity, webcast participants will be able to: DEFINE resistant hypertension; UNDERSTAND the causes of secondary hypertension and workup; DIAGNOSED resistant hypertension, identify those who require screening for secondary workup; and UNDERSTAND appropriate testing and management of resistant hypertension and secondary hypertension.

You’ll also learn about the following:

  • Blood pressure targets
  • Common causes of resistant hypertension

You can find this and many other MedNet21 programs on the OSU – CCME website.

Call our MedNet21 Program Manager at 614.293.3473 for more details about subscribing to MedNet21 as a hospital or as an individual. You can also e-mail him at derrick.freeman@osumc.edu.

On-line CME Discusses Acute and Chronic Sinusitis

OSUWexnerbloglogo2014 On-line CME Discusses Acute and Chronic Sinusitis. Sinuses have evolved in a lot of different ways to serve different purposes and they gave our ancestors important survival advantages. But when your head is all stopped up, your nose is running, and you have an excruciating pain above your cheek, you don’t really care, you just want to get better. Every year, about 30 million Americans get acute sinusitis and one out of every eight people have chronic sinusitis. On this CME webcast, we’re going to tell you everything you need to know about acute and chronic sinusitis. Joining our moderator in the studio is the Director of the Division of Sinus and Allergy here at Ohio State, Assistant Professor of Otolaryngology, Dr. Bradley Otto.

View a video introduction of this webcast

What you’ll learn in this webcast

As a result of this educational activity, webcast participants will be able to: UNDERSTAND the basic workup of patients with rhinosinusitis; and DEVELOP an understanding of the conditions that mimic or concomitantly exist with rhinosinusitis.

You’ll also learn about the following:

  • Challenges of diagnosing acute sinusitis
  • Chronic sinusitis
  • When to consult the otolaryngologist
  • The sinuses in systemic disease
  • Sinusitis surgery
  • Sinus stents

You can find this and many other MedNet21 programs on the OSU – CCME website.

Call our MedNet21 Program Manager at 614.293.3473 for more details about subscribing to MedNet21 as a hospital or as an individual. You can also e-mail him at derrick.freeman@osumc.edu.

New Developments in Lung Cancer Treatment

OSUWexnerbloglogo2014 New Developments in Lung Cancer Treatment. Lung cancer now accounts for 14% of all cancers but it is the most common cause of cancer death, In fact, more people die each year from lung cancer than from colon cancer, breast cancer, and prostate cancer combined. The 5-year survival rate of lung cancer is only 18% but the good news is that we have a lot of new medications that are giving patients with lung cancer longer and better lives. On our CME webcast, to discuss new treatments in lung cancer, are two of Ohio State’s experts in the management of lung cancer. Joining our moderator, Dr. Jim Allen, we have Dr. Greg Otterson who is a Professor of Internal Medicine from the Division of Medical Oncology and Dr. Erin Bertino, an Assistant Professor of Internal Medicine, also from the Division of Medical Oncology.

View a video introduction of this webcast

What you’ll learn in this webcast

As a result of this educational activity, webcast participants will be able to: GAIN an understanding of the importance of genomic testing in the initial workup of patients with lung cancer. EXPLAIN the evolving role of immune mediated therapy in lung cancer; RECOGNIZE the clinical benefit for patients receiving targeted therapies; and DESCRIBE the patient characteristics commonly associated with actionable mutations in lung cancer.

You’ll also learn about the following:

  • The most fatal of all common cancers
  • Evolving chemotherapy treatment of lung cancer
  • Sub-classifying adenocarcinomas
  • Squamous cell lung cancer treatment
  • Large cell undifferentiated lung cancer

You can find this and many other MedNet21 programs on the OSU – CCME website.

Call our MedNet21 Program Manager at 614.293.3473 for more details about subscribing to MedNet21 as a hospital or as an individual. You can also e-mail him at derrick.freeman@osumc.edu.